Published online May 14, 2018. doi: 10.3748/wjg.v24.i18.1962
Peer-review started: March 30, 2018
First decision: April 19, 2018
Revised: April 25, 2018
Accepted: May 6, 2018
Article in press: May 6, 2018
Published online: May 14, 2018
Processing time: 43 Days and 4.9 Hours
Innate lymphoid cells (ILCs) are defined as a distinct arm of innate immunity. According to their profile of secreted cytokines and lineage-specific transcriptional factors, ILCs can be categorized into the following three groups: group 1 ILCs (including natural killer (NK) cells and ILC1s) are dependent on T-bet and can produce interferon-γ; group 2 ILCs (ILC2s) are dependent on GATA3 and can produce type 2 cytokines, including interleukin (IL)-5 and IL-13; and, group 3 ILCs (including lymphoid tissue-like cells and ILC3s) are dependent on RORγt and can produce IL-22 and IL-17. Collaborative with adaptive immunity, ILCs are highly reactive innate effectors that promptly orchestrate immunity, inflammation and tissue repair. Dysregulation of ILCs might result in inflammatory disorders. Evidence regarding the function of intrahepatic ILCs is emerging from longitudinal studies of inflammatory liver diseases wherein they exert both physiological and pathological functions, including immune homeostasis, defenses and surveillance. Their overall effect on the liver depends on the balance of their proinflammatory and antiinflammatory populations, specific microenvironment and stages of immune responses. Here, we review the current data about ILCs in chronic liver disease progression, to reveal their roles in different stages as well as to discuss their therapeutic potency as intervention targets.
Core tip: Innate lymphoid cells (ILCs), mirroring both the phenotypes and functions of T cells, have been defined as a distinct arm of innate immunity. There has been a marked increase in the studies investigating the dysregulation of ILCs in chronic liver pathologies. This manuscript presents a comprehensive overview of the state of ILCs, including the fundamental concepts as well as summarizing their ambiguous roles in the progression of the chronic liver hepatitis, fibrosis and carcinoma. It also provides an insight into the current research gaps and indicates the therapeutic potency and development direction of future research of ILCs.